Premium
Individualized Pharmacokinetic Monitoring Results in Less Aminoglycoside‐Associated Nephrotoxicity and Fewer Associated Costs
Author(s) -
Streetman Daniel S.,
Nafziger Anne N.,
Destache Christopher J.,
Bertino Joseph S.
Publication year - 2001
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.21.5.443.34490
Subject(s) - aminoglycoside , nephrotoxicity , medicine , clindamycin , pharmacokinetics , piperacillin , vancomycin , odds ratio , antibiotics , toxicity , biology , genetics , bacteria , microbiology and biotechnology , pseudomonas aeruginosa , staphylococcus aureus
Study Objective. To examine the impact of individualized pharmacokinetic monitoring (IPM) on the development of aminoglycoside‐associated nephrotoxicity (AAN). Design. Retrospective case‐control study. Setting. Two teaching hospitals. Subjects. Two thousand four hundred five patients who received aminoglycosides. Intervention. Aminoglycoside therapy dosed by either IPM or physicians' directions. Measurements and Main Results. Patients receiving IPM were significantly less likely to develop AAN by both univariate (7.9% vs 13.2%, p=0.02) and multivariate methods (odds ratio 0.42, p=0.002). Female sex was protective against AAN. Age 50 years and above, high initial aminoglycoside trough, long duration of therapy, and concurrent piperacillin, clindamycin, or vancomycin increased risk of AAN. We estimated that IPM decreased AAN costs by $90,995/100 patients. Conclusion. Individualized pharmacokinetic monitoring significantly decreased the frequency of AAN and its associated economic costs.